newsfilter
← Latest News
GlobeNewswire·

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate